Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22
at seekingalpha.com (Thu, 26-Mar 12:42 AM)
FDA Greenlights Atossa’s (Z)-Endoxifen Study, Advancing Hope for Metastatic Breast Cancer Treatment
Market Chameleon (Tue, 6-Jan 11:48 AM)
